Mr. Vanktesh Kumar | Pharma | Young Researcher Award
Lovely professional university, India
Vanktesh Kumar, in Ludhiana, Punjab, is a passionate and skilled medicinal chemist with expertise in analytical, synthetic, and pharmaceutical chemistry. Currently pursuing his Ph.D. in Pharmaceutical Chemistry from Lovely Professional University, he has held pivotal research roles at MacLeods Pharmaceuticals Ltd. and the Regional Center for Biotechnology. His research bridges cancer biology, nanotechnology, and drug discovery, focusing on kinase inhibitors and herbal neurotherapeutics. With multiple impactful publications and technical skills, Vanktesh continues to make significant contributions to drug design, synthesis, and pharmaceutical innovation.
Profile
π Education
Vanktesh Kumar is currently pursuing his Ph.D. in Pharmaceutical Chemistry (2024) from Lovely Professional University, following an M.Pharm in the same discipline (2021) with a CGPA of 8.60. He earned his B.Pharm from Govt. Institute of Pharmaceutical Sciences (2019) with 8.52 CGPA. Prior to that, he studied Intermediate-Science (PCB) at SCD Govt. College (2015), securing 89.56%, and completed his matriculation from Mukt Vidya Mandir School in 2013 with 79.56%. His strong academic background in pharmaceutical sciences and analytical chemistry underpins his robust research capabilities and technical excellence in the field.
πΌ Experience
Vanktesh has served as an Executive Research Analyst at MacLeods Pharmaceuticals Ltd. (2021β2023), where he conducted rigorous analytical evaluations of drug compounds using HPLC, UV-Vis, AAS, and more, contributing to drug development and quality control. Since 2023, heβs been working at RCB, Faridabad, in collaboration with NII and AIIMS New Delhi, on cancer biology projects involving lipidomics, nanotech, and patient-derived cancer cells. His work also includes biomarker identification and post-surgical outcome tracking, showcasing his deep involvement in translational research with clinical relevance.
π Awards & Honors
Vanktesh Kumar has been recognized for his outstanding contributions to pharmaceutical research through multiple peer-reviewed publications in reputed journals and book chapters. His scholarly work includes comprehensive reviews, docking studies, and experimental designs that reflect high-level academic and practical insight. Contributing chapters to international scientific volumes by publishers like Walter de Gruyter and Academic Press, and publishing in journals such as Current Medicinal Chemistry and Chemical Biology & Drug Design, affirms his status as an emerging researcher. His ongoing doctoral work and research collaborations with prestigious institutions highlight his dedication and growing recognition.
π¬ Research Focus
Vanktesh focuses on medicinal and pharmaceutical chemistry, specifically drug design, synthesis, and evaluation of kinase inhibitors for cancer therapy. His doctoral project targets AXL kinase with novel 2-(1,3-dioxoisoindolin-2-yl)-N-substituted phenyl-acetamide derivatives using in silico modeling, synthesis, and in vitro evaluation. Heβs also investigated herbal neuroprotective agents, isolating bioactives using LC-MS, HPLC, and NMR. His work spans nanomedical drug delivery, phytopharmacology, and computational chemistry. Combining analytical methods with synthetic innovation, his goal is to discover and develop next-generation therapeutics addressing oncology, neurology, and metabolic disorders.
Conclusion
Mr. Vanktesh Kumar demonstrates outstanding potential as a young medicinal chemist, blending analytical expertise, computational modeling, and applied research in oncology and neuropharmacology. His publications, technical proficiencies, and current Ph.D. work on targeted cancer therapy represent significant scientific merit. With added focus on global collaboration, leadership roles, and translational outputs like patents or clinical leads, he would be a strong and deserving candidate for the Young Scientist Award.
Publication
Title: Alphaβamylase as molecular target for treatment of diabetes mellitus: A comprehensive review
Year: 2021
Authors: N Kaur, V Kumar, SK Nayak, P Wadhwa, P Kaur, SK Sahu
Cited by: 275
Title: Clinical evidence on the effects of saffron (Crocus sativus L.) in anxiety and depression
Year: 2022
Authors: V Kumar, N Kaur, P Wadhwa
Cited by: 13
Title: Role of tyrosine kinases and their inhibitors in cancer therapy: a comprehensive review
Year: 2023
Authors: V Kumar, N Kaur, S Sahu, V Sharma, D Kumar, A Sharma, P Wadhwa
Cited by: 11
Title: Nanomedical drug delivery for neurodegenerative disease
Year: 2022
Authors: N Kaur, V Kumar, T Mahender, I Maji, S Mahajan, M Aalhate, PK Singh, β¦
Cited by: 11
Title: Phytochemistry and Pharmacology of Indian Traditional Plant Hyssop (Hyssopus officinalis L.): A Review
Year: 2023
Authors: V Kumar, N Kaur, A Kaur, P Wadhwa
Cited by: 7
Title: Homoisoflavonoids: isolation, chemical synthesis strategies and biological activities
Year: 2020
Authors: V Kumar, SK Nayak
Cited by: 4
Title: A review over the effect of heavy metal in metabolism of Brassica juncea (L.) and Myristica fragrans
Year: 2021
Authors: V Kumar, N Kaur, P Wadhwa
Cited by: 3
Title: Role of structural genomics in drug discovery
Year: 2024
Authors: A Mehra, V Kumar, B Kapoor, M Gulati, P Wadhwa
Title: Computational Drug Discovery: Molecular Simulation for Medicinal Chemistry
Year: 2024
Authors: MGP Anuradha Mehra, Vanktesh Kumar, Bhupinder Kapoor
Title: A Review on Inhibitory Action of Tyrosine Kinase Inhibitors (TKI) by Curbing the ATP-Tyrosine Kinase Interactions
Year: 2023
Authors: V Kumar, N Kaur
Title: CULTIVATION AND COLLECTION OF SOME PLANTS WITH THEIR SIGNIFICANCE ROLE IN DIABETES MELLITUS: A COMPREHENSIVE REVIEW
Year: 2021
Authors: N KAUR, V KUMAR, P WADHWA
Title: A Review on Role of Cyclin-Dependent Kinase (CDK) Enzyme and their Inhibitor
Year: 2020
Authors: S Dey, V Kumar, P WadhwaTitle: The Important Nutritional and Wonderful Health Benefits of Cashew (Anacardium occidentale L.)
Year: Not listed
Authors: V Kumar, N Kaur, A Kaur, P Wadhwa